These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

768 related items for PubMed ID: 15597070

  • 1. Meningococcal C vaccines: the Canadian experience.
    De Wals P.
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease.
    De Wals P, Nguyen VH, Erickson LJ, Guay M, Drapeau J, St-Laurent J.
    Vaccine; 2004 Mar 12; 22(9-10):1233-40. PubMed ID: 15003652
    [Abstract] [Full Text] [Related]

  • 3. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada.
    Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R, Canadian Immunization Monitoring Program, Active (IMPACT).
    Pediatr Infect Dis J; 2009 Mar 12; 28(3):220-4. PubMed ID: 19209096
    [Abstract] [Full Text] [Related]

  • 4. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.
    Larrauri A, Cano R, García M, Mateo Sd.
    Vaccine; 2005 Jul 14; 23(32):4097-100. PubMed ID: 15908059
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness of serogroup C meningococcal polysaccharide vaccine: results from a case-control study in Quebec.
    De Wals P, Deceuninck G, De Serres G, Boivin JF, Duval B, Remis R, Massé R.
    Clin Infect Dis; 2005 Apr 15; 40(8):1116-22. PubMed ID: 15791510
    [Abstract] [Full Text] [Related]

  • 6. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
    De Wals P, Coudeville L, Trottier P, Chevat C, Erickson LJ, Nguyen VH.
    Vaccine; 2007 Jul 20; 25(29):5433-40. PubMed ID: 17560695
    [Abstract] [Full Text] [Related]

  • 7. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
    Pace D.
    Expert Rev Vaccines; 2009 May 20; 8(5):529-42. PubMed ID: 19397410
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada.
    De Wals P, Deceuninck G, Lefebvre B, Boulianne N, De Serres G.
    Pediatr Infect Dis J; 2011 Jul 20; 30(7):566-9. PubMed ID: 21326136
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine.
    De Wals P, Deceuninck G, Boulianne N, De Serres G.
    JAMA; 2004 Nov 24; 292(20):2491-4. PubMed ID: 15562128
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [The first effect of the national vaccination campaign against meningococcal-C disease: a rapid and sharp decrease in the number of patients].
    de Greeff SC, de Melker HE, Spanjaard L, van den Hof S, Dankert J.
    Ned Tijdschr Geneeskd; 2003 Jun 07; 147(23):1132-5. PubMed ID: 12822525
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
    Shepard CW, Ortega-Sanchez IR, Scott RD, Rosenstein NE, ABCs Team.
    Pediatrics; 2005 May 07; 115(5):1220-32. PubMed ID: 15867028
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Serogroup C meningococcal conjugate vaccines: new preparations. Effective from age two months.
    Prescrire Int; 2003 Apr 07; 12(64):43-6. PubMed ID: 12675020
    [Abstract] [Full Text] [Related]

  • 18. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.
    Welte R, van den Dobbelsteen G, Bos JM, de Melker H, van Alphen L, Spanjaard L, Rümke HC, Postma MJ.
    Vaccine; 2004 Dec 09; 23(4):470-9. PubMed ID: 15530695
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.